Biohaven starts Phase 3 trial of BHV-1300 for Graves' disease

June 29, 2026 7:31 AM

Biohaven Ltd. (NYSE: BHVN) announced the enrollment of the first patient in a pivotal Phase 3 trial of BHV-1300, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found